RFAMR 最新10-Q变化
将 RFAMR 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-21 与上一份 10-Q · 2026-04-30
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +10 | −4 | ~7 | 7 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 2 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | −1 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-21
On July 9, 2026, the Company entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Company, HCC Healthcare Pte. Ltd., a Singapore private company limited by shares (“HCC Healt…
The Business Combination Agreement and the transactions contemplated thereby were approved by the boards of directors of the Company, HCC Healthcare and Merger Sub.
The Business Combination Agreement provides for, among other things, the following transactions: (i) immediately prior to the closing of the transactions contemplated in the Business Combination Agreement (the “Closing”), HCC Healthcare will effect a recapitalization (the “Recapitalization”) convert…
In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share of the Company (the “Acquiror Ordinary Share”) will automatically be cancelled and converted into such one newly issued Company Ordinary Share as determine…
The obligations of RFAC III and HCC Healthcare to consummate the Business Combination are subject to certain closing conditions, including but not limited to: (i) the a registration statement on Form F-4 (the “Registration Statement”) having become effective; (ii) approval by the RFAC III and HCC He…
相对上期删除的文字 · 来源:10-Q · 2026-04-30
We have neither engaged in any operations nor generated any revenues to date. Our only activities from September 15, 2025 (inception) through March 31, 2026 were organizational activities and those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public O…
For the three months ended March 31, 2026, we had a net income of $725,986, which consisted of change on fair value of over-allotment liability of $422,000 and interest earned on cash held in Trust Account of $403,232, partially offset by general and administrative costs of $99,246.
For the six months ended March 31, 2026, we had a net income of $673,033, which consisted of change on fair value of over-allotment liability of $422,000 and interest earned on cash held in Trust Account of $403,232, partially offset by general and administrative costs of $152,199.
We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual a…
其他信息
相对上期删除的文字 · 来源:10-Q · 2026-04-30
On March 17, 2026, the Company entered into a non-binding letter of intent with a prospective target regarding a potential business combination. There can be no assurance that a definitive agreement will be executed or that the transaction will be consummated.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议